Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(22%)
Results Posted
100%(6 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_2
3
33%
Ph phase_3
4
44%

Phase Distribution

2

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Active, not recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 34 (44.4%)

Trials by Status

active_not_recruiting111%
completed667%
terminated111%
recruiting111%

Recent Activity

Clinical Trials (9)

Showing 9 of 9 trials
NCT07286370Phase 2

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

Recruiting
NCT05743881Phase 1

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Active Not Recruiting
NCT03606512Phase 1

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Completed
NCT04645966Phase 2

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Terminated
NCT04819113Phase 3

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Completed
NCT01144663Phase 3

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

Completed
NCT00514904Phase 3

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Completed
NCT01839175Phase 3

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Completed
NCT00715910Phase 2

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

Completed

All 9 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
9